Clinical guidelines for the management of gastrointestinal stromal tumors;Raccomandazioni cliniche per la diagnosi, la terapia ed il follow-up dei tumori stromali gastrointestinali

Clinica Terapeutica

Volumn 157, Issue 3, 2006, Pages 283-299

  Lopez, Massimo ^a   Comandone, A ^b   Adamo, V ^b   Apice, G ^b   Bearzi, I ^b   Bracci, R ^b   Carlini, M ^b   Carpano, S ^b   Condorelli, S ^b   Covello, R ^b   Cucchiara, G ^b   Di Filippo, F ^b   Doglietto, G B ^b   Ficorella, C ^b   Garofalo, A ^b   Gebbia, N ^b   Giuliani, F ^b   Massidda, B ^b   Messerini, L ^b   Palmirotta, R ^b   Tonelli, F ^b   Vidiri, A ^b   more..

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b NONE

Author keywords

GIST; Guidelines; Imatinib; Sunitinib

Indexed keywords

CD34 ANTIGEN; DESMIN; IMATINIB; PROTEIN S 100; SMAD PROTEIN; STEM CELL FACTOR RECEPTOR; SUNITINIB;

ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DRUG HYPERSENSITIVITY; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; REVIEW;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DECISION TREES; DISEASE PROGRESSION; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PRACTICE GUIDELINES; PYRIMIDINES;

EID: 33845399681     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. PNLG-Piano Nazionale Linee Guida. Manuale metodologico. Come produrre, diffondere e aggiornare raccomandazioni per la pratica clinica. Agenzia per i Servizi Sanitari Regionali. 2002
2. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J: Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 1999; 281: 1900-15
3. Nilsson B, Bumming P, Meis-Kindblom JM, et al.: Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer 2005; 103: 821-9
4. Lopez M: Tumori stromali gastrointestinali. In: Lopez M: Oncologia Medica Pratica (ed. 2). Società Editrice Universo, Roma, 2005
5. Reith JD, et al.: Extragastrointestinal (soft tissue) stromal tumors: An analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13: 577-85
6. Heinrich MC, Rubin BP, Longley JL, et al.: Biology and genetic aspects of gastrointestinal stromal tumours: kit activation and cytogenetics alterations. Hum Pathol 2002; 3: 484-95
7. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 2003; 21: 4342-9
8. Debiec-Rychter M, Wasag B, Stul M, et al.: Gastrointestinal stromal tumors (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004; 202: 430-8
9. Medeiros F, Corless CL, Duensing A, et al.: KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28: 889-94
10. West RB, Corless CL, Chen X, et al.: The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004; 165: 107-13
11. Blay P, Astudillo A, Buesa JM, et al.: Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 2004; 10: 4089-95
12. Duensing A, Joseph NE, Medeiros F, et al.: Protein kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 2004; 64: 5127-31
13. Motegi A, Sakurai S, Nakayama H, et al.: PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. Pathol Int 2005; 55: 106-12
14. Ghanem N, Altehoefer C, Furtwangler A, et al.: Computed tomography in gastrointestinal stromal tumors. Eur Radiol 2003; 13: 669-78
15. Burkill GJ, Badran M, Al-Muderis O, et al.: Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003; 226: 527-32
16. Nishida T, Hirota S: Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000; 15: 1293-1301
17. GIST Symposium: Hum Pathol 2002; 33: 456-95
18. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80
19. Verweij J, Casali PG, Zalcberg J, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-34
20. Linton KM, Taylor MB, Radford JA, et al.: Response evaluation in GIST treated with imatinib - misdiagnosis of disease progression on CT due to cystic change in liver metastases. Proc Am Soc Clin Oncol 2005; 23: 827s (abstr. 9047)
21. Chen MYM, Bechtold RE, Savage PD: Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (Imatinib mesylate). Am J Roentenol 2002; 179: 1059-62
22. Choi H, Charnsangavej C, de Castro Faria S, et al.: CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004; 183: 1619-28
23. Stroobants S, Goeminne J, Seegers M, et al.: 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012-20
24. Choi H, Charnsangavej C, Macapinlac HA, et al.: Correlation of computerized tomography (CT) and proton emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate. Proc Am Soc Clin Oncol 2003; 22: 819 (abstr. 3290)
25. DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8
26. Benjamin RS, Rankin C, Fletcher C, et al.: Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 2003; 22: 814 (abstr. 3271)
27. Rankin C, Von Mehren M, Blanke C, et al.: Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol 2004; 23: 819, (abstr. 9005)
28. Blackstein ME, Rankin C, Fletcher C, et al.: Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial. Proc Am Soc Clin Oncol 2005; 23: 818s (abstr. 9010)
29. Le Cesne A, Perol D, Ray-Coquad I, et al.: Interruption of imatinib (IM) in GIST patients with advanced disease: Updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life. Proc Am Soc Clin Oncol 2005, 23: 823s (abstr. 9031)
30. Van Den Abbeele AD, Badawi RD, Manola J, et al.: Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning (abstract). 2004 ASCO Proceedings (post-meeting edition). J Clin Oncol 2004; 22: 198 (abstr)
31. Judson I, Ma P, Peng B, et al.: Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005; 55: 379-86
32. Maki RG, Fletcher JA, Heinrich MC, et al.: Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2005; 23: 818s (abstr. 9011)
33. Demetri GD, Desai J, Fletcher JA, et al.: SU11248, a multitargeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) (abstract). 2004 ASCO Proceedings (post-meeting edition). J Clin Oncol 2004; 22: 195 (abstr)
34. Demetri GD, George S, Heinrich MC, et al.: Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol 2003; 22: 814 (abstr. 3273)
35. Demetri G, van Oosterom A, Garrett C, et al.: Sunitinib malate (SU11248) prolongs progression-free and overall survival for GIST patients after failure of imatinib mesylate therapy: update of a phase III trial. ECCO13 The European Cancer Conference, Abstract Book EJC Supplements 3: 203, 2005 (abstr. 716)
36. van Oosterom A, Reicherdt P, Blay J-Y, et al.: A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update. Proc Am Soc Clin Oncol 2005; 23: 824s (abstr. 9033)